Healthcare startup Suki raises $70 million to build AI assistants for hospitals
Adds detail on customers in paragraph 6
Update with details on healthcare partnership in paragraph 6
By Krystal Hu
Oct 10 (Reuters) - Suki, a startup that offers to build artificial intelligence (AI) assistants in healthcare, has raised $70 million in a Series D round, the company told Reuters, as investors place bets on the adoption of generative AI-powered applications in the sector.
The funding round was led by London-based tech investment firm Hedosophia, with additional investments from Venrock and March Capital. This brings Suki's total funding to $165 million.
Redwood City, California-based Suki did not disclose its valuation, but a person familiar to the funding round said the latest proceeds valued the company at about $500 million.
Founded in 2017 by former Google and Flipkart executive Punit Soni, Suki develops AI voice assistant to reduce the administrative workload for healthcare providers. Its primary products Suki Assistant and Suki Platform have seen increased adoption since the boom of OpenAI's ChatGPT, as healthcare systems across the country explore how the technology can better aid doctors' clinical work.
"When the AI trend kicked in, every health system wanted to have an AI strategy," Soni said, adding that the company has built proprietary tech stack by being in the space early.
The company capitalized on the demand, saying it now has established partnerships with over 300 health systems such as St. Mary's Healthcare in New York. Suki also touts the broadest integration of Electronic Health Record systems (EHRs), working with Epic, Oracle-owned Cerner, Athena, as well as MEDITECH.
Soni said the latest funding will be used to accelerate product development, adding more features to the assistant and build tools to manage the use of multiples AI models.
Suki competes with Microsoft-owned Nuance, whose Dragon Medical One is widely used for its speech recognition and clinical documentation, as well as other startups such as Abridge, which has raised $150 million from VC investors to train medical AI models.
Reporting by Krystal Hu in New York; Editing by Sherry Jacob-Phillips and Nick Zieminski
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
